Palazestrant is a small molecule commercialized by Olema Pharmaceuticals, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 10 clinical trials, of which 5 are ongoing, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Palazestrant’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Palazestrant is expected to reach an annual total of $686 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Palazestrant Overview

Palazestrant (OP-1250) is under development for the treatment of metastatic HR positive and HER2 negative breast cancer, endometrial cancer, ER positive and HER2 positive breast cancer and gynaecological malignancies. It is administered by oral route in the form of tablet or pill. The drug candidate is a selective estrogen receptor degrader (SERD) and acts by targeting estrogen receptor (ESR).

Olema Pharmaceuticals Overview

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company that discovery, development, and commercialization of next-generation targeted therapies for women’s cancers. The company’s lead product candidate is palazestrant (OP-1250), a novel, orally-available small molecule with dual activity as both a complete estrogen receptor antagonist and selective estrogen receptor degraded. Olema Pharmaceuticals operates in multiple locations, including San Francisco, California, and Cambridge, Massachusetts, the US. Olema Oncology is headquartered in San Francisco, California, United States.
The operating loss of the company was US$105 million in FY2023, compared to an operating loss of US$107 million in FY2022. The net loss of the company was US$96.7 million in FY2023, compared to a net loss of US$104.8 million in FY2022.

For a complete picture of Palazestrant’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.